1201187-46-3Relevant articles and documents
Development of a Scalable Enantioselective Synthesis of JAK Inhibitor Upadacitinib
Bhagavatula, Lakshmi,Christesen, Alan,Dunn, Travis B.,Ickes, Andrew,Kotecki, Brian J.,Marek, James C.,Morrill, Westin H.,Moschetta, Eric,Mulhern, Mathew,Rasmussen, Michael,Reynolds, Troy,Rozema, Michael J.,Yu, Su
, (2021/10/21)
Process development of a six-stage synthesis of upadacitinib, a JAK1 inhibitor, is described. It is highlighted by an enantioselective and diastereoselective hydrogenation of a tetrasubstituted olefin to set the two pyrrolidine stereocenters. Preparation of the main fragments and strategies to link them together, optimization of the imidazole cyclization, and in-depth understanding of the formation of the urea moiety at the final stage are discussed.
Preparing method of (5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-yl)methyl carbamate
-
, (2019/10/01)
The invention relates to a preparing method of (5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-yl)methyl carbamate. In the method, 5-bromo-4,7-diazindole serves as the initial raw material, and (5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-yl)methyl carbamate is prepared thr
Influenza virus replication inhibitors and uses thereof (by machine translation)
-
, (2019/10/01)
The invention provides a compound as an influenza virus replication inhibitor, a method for preparing the same, a pharmaceutical composition containing the compound and application. (by machine translation)